

Title	FOA number(s)	FOA sponsor (e.g. NICHD, FDA)	Application Deadline	Brief Description
<u>Maternal Nutrition and Pre-pregnancy Obesity: Effects on Mothers, Infants and Children (R01 Clinical Trial Optional)</u>	PA-18-135	Health and Human Services- National Institutes of Health 11	7-May-2018	This Funding Opportunity Announcement (FOA) encourages applications to improve health outcomes for women, infants and children, by stimulating interdisciplinary research focused on maternal nutrition and pre-pregnancy obesity.
<u>Testing Newborn Dried Blood Spots for Diagnosis of Congenital Cytomegalovirus Infection</u>		Department of Health and Human Services: Centers for Disease Control and Prevention	8-May-2018	The Centers for Disease Control and Prevention intends to award a sole source firm fixed price contract to Minnesota Department of Health (MDH) for the purchase Dried Blood Spots (DBS) from the MDH Newborn Screening Laboratory.

<u>Newborn Screening Data Repository and Technical Assistance Program</u>	HRSA-18-080	Health and Human Services-HRSA	22-May-2018	<p>The purpose of this cooperative agreement is to enable the recipients to: 1) Enhance, improve and expand the ability of states and local public health agencies to provide screening, counseling, or health care services to newborns and children having or at risk for heritable disorders; 2) Assist in providing health care practitioners and newborn screening laboratory personnel with education in newborn screening and training in relevant and new technologies in newborn screening and congenital, genetic and metabolic disorders; and 3) Establish, maintain, and operate a system to assess and coordinate follow-up and treatment relating to congenital and genetic (including metabolic) disorders identified through newborn screening.</p>
---	-------------	--------------------------------	-------------	---

<u>Impact Grants</u>		Cystic Fibrosis Foundation	31-May-2018	The Cystic Fibrosis Foundation (CFF) offers funding to individuals or organizations that have or would like to develop a program or project proposed by individuals with cystic fibrosis (CF), or their families, that relates to the CF community and supports individuals with CF and their families in their daily lives.
<u>Genomic Centers for Infectious Diseases (U19 Clinical Trial Not Allowed)</u>	RFA-AI-18-004	National Institutes of Health, National Institute of Allergy and Infectious Diseases	22-Jun-2018	The purpose of this initiative is to support Genomic Centers for Infectious Diseases (GCID) to promote broad use and expand the application of genomics technologies and computational analysis to understand infectious diseases, with an emphasis on pathogens, their interaction with the host and microbiome, and to aid in the development of novel genomics-based tools to diagnose, prevent and treat infectious diseases.

<p><u>Newborn Screening New Condition Implementation: Capacity Building and Quality Improvement through Data Harmonization</u></p>	<p>CDC-RFA-EH18-1804</p>	<p>Centers for Disease Control - NCEH</p>	<p>29-Jun-2018</p>	<p>To increase the number of states and territories with fully implemented newborn screening programs.</p>
<p><u>Natural History Studies for Rare Disease Product Development: Orphan Products Research Project Grant (R01)</u></p>	<p>RFA-FD-16-043</p>	<p>Food and Drug Administration</p>	<p>15-Oct-2018</p>	<p>The objective of FDA's Orphan Products Natural History Grants Program is to support studies that advance rare disease medical product development through characterization of the natural history of rare diseases/conditions, identification of genotypic and phenotypic subpopulations, and development and/or validation of clinical outcome measures, biomarkers and/or companion diagnostics</p>

<p><u>Natural History of Disorders Identifiable by Screening of Newborns (R01 Clinical Trial Optional)</u></p>	<p>PAR-18-090</p>	<p>Health and Human Services- National Institutes of Health 11</p>	<p>7-May-2019</p>	<p>This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a necessary element to facilitate appropriate interventions for infants identified by newborn screening.</p>
<p><u>Natural History of Disorders Identifiable by Screening of Newborns (R01)</u></p>	<p>PAR-16-061</p>	<p>Health and Human Services- National Institutes of Health 11</p>	<p>8-May-2019</p>	<p>This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening</p>

<u>Ethical, Legal and Social Implications (ELSI) of Genomics Small Research Grant Program (R03)</u>	PA-17-445	NHGRI, NCI, NIA, NIAID, NICHD, NIDCD, NIDA, NIEHS	7-Sep-2020	This Funding Opportunity Announcement (FOA) invites Small Research Grant (R03) applications to study the ethical, legal and social implications (ELSI) of human genome research
<u>Ethical, Legal, and Social Implications (ELSI) of Genomics Exploratory/Developmental Research Grant Program (R21)</u>	PA-17-446	NHGRI, NCI, NIA, NIAID, NICHD, NIDCD, NIDA, NIEHS	7-Sep-2020	This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research.
<u>Innovative Therapies and Tools for Screenable Disorders (R01 Clinical Trial Optional)</u>	PAR-18-689	National Institutes of Health	7-May-2021	This FOA encourages research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future.

<u>Innovative Therapies and Tools for Screenable Disorders (R03 Clinical Trial Optional)</u>	PAR-18-690	National Institutes of Health	7-May-2021	This FOA encourages research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future.
<u>Innovative Therapies and Tools for Screenable Disorders (R21 Clinical Trial Optional)</u>	PAR-18-691	National Institutes of Health	7-May-2021	This FOA encourages research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future.

<p><u>Content Development for the Newborn Screening Clearinghouse</u></p>		<p>The Health Resources and Services Administration (HRSA), Maternal and Child Health Bureau (MCHB)</p>	<p>Ongoing</p>	<p>Develop and maintain a central clearinghouse of newborn screening information and provide expertise on newborn screening to inform this project.</p>
<p><u>Malonic Aciduria – One (1)</u></p>		<p>NORD/ The Hope Fund</p>	<p>Ongoing</p>	<p>The purpose of the NORD Research Grant Program is to encourage meritorious scientific and clinical studies designed to improve the diagnosis or therapy of rare “orphan” diseases.</p>
<p><u>Child, Newborn, and Maternal Health Project</u></p>	<p>RFA-391-13-000009</p>	<p>USAID-PAK</p>		<p>The purpose of this amendment is to cancel the Request for Child, Newborn, and Maternal Health Activity.</p>